Dr. Loïc Maurel, president of Exonhit’s management board stated, “Knowing that 5.4 million Americans are living with Alzheimer’s and that the disease costs $183 billion per year, significant efforts have to be made to identify Alzheimer’s at its very early stages to improve the management of the disease. Our ultimate goal is to define the clinical utility of AclarusDx to provide primary care physicians with a diagnostic tool that will help them identify patients at high risk of having Alzheimer’s and to prescribe a complete diagnostic workup.”  

 

---

 

Exonhit extends strategic collaboration with Allergan  

 

PARIS—ExonHit SA also announced in November the extension of its existing drug discovery collaboration with Allergan Sales LLC. The collaboration was initiated in December 2002 and extended several times. It now is further extended until December 2013.  

 

The collaboration will continue to focus on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology.

 

“We are very pleased that our longstanding strategic collaboration with Allergan will continue until the end of 2013. The collaboration has created significant value for both organizations, and we are optimistic that it will continue to build upon recent successes and advance additional existing preclinical programs into clinical development,” said Loïc Maurel, CEO of Exonhit, in a statement.

 

Detailed financial terms were not disclosed.